Proton therapy (PT) combined with concurrent chemotherapy for locally advanced non-small cell lung cancer with negative driver genes

Table 3 Organs at Risk and Doses Received(Mean ± SE)

Radiation Type	Lung			Spinal cord	Heart		Esophagus
	V5 (%)	V20 (%)	MLD (Gy)	Dmax (Gy)	V40 (%)	Dmax(Gy)	Dmax(Gy)	Dmean(Gy)
X-ray	56.72 ± 1.89	23.95 ± 0.12	14.01 ± 0.20	39.75 ± 0.67	16.75 ± 0.42	68.49 ± 0.34	67.06 ± 0.28	31.59 ± 0.21
Proton P t df	26.22 ± 1.41 *** 11.83 60	19.79 ± 0.94 *** 5.31 60	10.98 ± 0.39 *** 7.54 60	40.57 ± 0.55 0.38 0.88 60	2.79 ± 0.11 *** 26.84 60	54.36 ± 0.21 *** 31.47 60	67.04 ± 0.17 0.96 0.05 60	32.67 ± 1.95 0.51 0.67 60

Note: Statistical results are presented as mean ± standard error, with P < 0.05 considered statistically significant(***: P<0.001, **:P<0.01, *:P<0.05)

ISSN: 1748-717X